Clinical: Therapy and observation S173 And the dose of prednisolone (PSL) at baseline was also significantly higher in the refractory group than the response group (p = 0.005). Multiple logistic regression analysis showed that high daily PSL dose (p = 0.032, 95% CI 1.014 1.363) at baseline and high CAI score at 7 days after achieving high trough level (p = 0.047, 95% CI 1.007 3.065) were significant predictive factors for the refractory to TA therapy. Conclusions: Higher activity and higher daily PSL dose at baseline, poor response at 7 days after achieving high trough level were predictive factors for refractory to TA therapy. These refractory patients should be changed to alternative treatment including surgery without missing the appropriate timing. Background: Leukocytapheresis (LCAP) has been reported to be a safe and effective treatment for active ulcerative colitis (UC). However, the factor predicting the efficacy of LCAP had not been yet established. The aim of this study was to perform the univariate analysis of the predictive factor for the efficacy of LCAP in patients with UC. Conclusions: This study demonstrates the clinical efficacy of LCAP in active UC patients and also indicates that the induction of remission by repeated sessions of LCAP therapy is important to maintain the long-term remission.
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Prediction of clinical responders to treatment with DIMS0150 a Toll-Like Receptor 9 agonist in therapy refractory ulcerative colitis patients Bottrop, Germany, 3 IBD unit Sophiahemmet and the Dept of Medicine, Karolinska Institutet, Stockholm, Sweden Background: Previous clinical studies suggest that local rectal administration of the Toll-Like Receptor 9 (TLR9) agonist in therapy refractory UC patients induced clinical response and remission. Clinical improvements were paralleled by a restoration of steroid sensitivity in vitro as determined by the use of specific biomarkers. The aim of the presented study was to determine whether patients mostly likely to benefit from DIMS0150 treatment could be identified through the use of these specific biomarkers. Methods: We investigated, in the context of a randomized, placebo controlled clinical study, whether screening of a preselection of steroid response genes could identify steroid refractory UC subjects most likely to respond to DIMS0150 treatment. Expression analysis of 34 steroid response genes were performed in vitro in peripheral blood mononuclear cells (PBMCs) derived from in 9 steroid refractory UC patients and compared to healthy volunteers. Clinical utility of the biomarkers was subsequently tested in a placebo controlled, randomized, double blinded study in active therapy resistant UC patients on concomitant steroid therapies. Results: We identified two biomarkers CD163 and TSP1 whose response to steroids was significantly enhanced when DIMS0150 was applied in vitro. Thirty-four subjects were randomized to receive a single rectal administration of placebo or 30 mg of DIMS0150. Blood derived PBMCs were obtained prior to dosing and assayed for evidence of a steroid sensitizing effect following steroid incubation in the presence of DIMS0150. Upon study completion and un-blinding, the biomarker assay correctly predicted a clinical response in over 90% of those patients positive for both biomarkers. The clinical response rate in this positively identified group was impressive being over 80% for active at weeks 1 and 4 with a delta of over 50% to placebo. By contrast, patients with a negative outcome for the biomarkers had a response rate no different to placebo being 14% and 27% at weeks 1 and 4 respectively. Conclusions: Using specific steroid response biomarkers, therapy refractory UC patients more likely to benefit from DIMS1050 treatment could be identified and illustrates the usefulness of a personalized treatment approach.
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Physician knowledge of reproductive issues in inflammatory bowel disease is highly variable Background: Reproductive care during inflammatory bowel disease (IBD) can be challenging in its multifactorial nature. Physicians must consider the impact of IBD and its treatment on fertility, pregnancy, and neonatal outcome. While women with inactive IBD have outcomes similar to the general population, patients with active IBD are faced with decreased fertility and varied fetal outcomes. There is a higher rate of voluntary childlessness in women with IBD compared to the general population, with this decision often being made because of the IBD diagnosis. Our previous study assessing patient knowledge of reproductive issues in IBD demonstrated that patient knowledge regarding reproductive issues in IBD was poor, despite 50% reported discussing these issues with their physicians. The aim of this study was to assess, in physicians treating women with IBD, their IBD-related reproductive knowledge and their practice in discussing this knowledge with IBD patients. Methods: Physicians attending a national IBD conference, and a provincial gastroenterology for general practitioners conference both in 2012, were invited to complete a survey package consisting of: 1) Crohn's and Colitis Pregnancy Knowledge (CCPKnow) score and 2) questionnaire regarding individual practice patterns. The validated CCPKnow score differentiates between poor (0 7), adequate (8 10), good (11 13) and very good (14 18) reproductive knowledge.
Results: The response rate was 53% (85/160). Gastroenterology trainees, general internists and gastroenterologists scored, 15.8+2.2, 17.0+1.4, and 16.9+1.7, and had higher CCPKnow scores than general practitioners (9.8+3.7) (p < 0.001). Characteristics that significantly influenced CCPKnow included years in practice, type of practice, total number of IBD patients and pregnant IBD patients seen per year. There were significant deficits in physician knowledge and use of medications in the reproductive period, some of which could be harmful to the pregnancy. Gastroenterologists (87%) and general internists (100%) were more likely to discuss family planning. Physicians with very good CCPKnow (84%) were more likely to discuss family planning and address medication issues appropriately. Conclusions: This is the first study to demonstrate that general practitioners have limited knowledge regarding reproductive issues in IBD compared to specialists. Furthermore, despite good knowledge, gastroenterologists and general internists have widely varied practices regarding the management of pregnant IBD patients.
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Physician-initiated treatment patterns of ulcerative colitis patients in the United Kingdom: a review of chart-abstracted data L. Yen 1 *, B.J. Katic 1 .
Shire Development LLC, Wayne, PA, United States
Background: Various treatment options exist for managing ulcerative colitis (UC) in the United Kingdom (UK). Relapseassociated treatment patterns, and the degree to which treatment options differ by physician specialty, however, have not been studied. This study aimed to describe common relapse-related treatment patterns for UC, both overall and by physician specialty. Methods: A retrospective chart review of UC patients diagnosed at least 1 year prior to study start was performed. General practitioners (GPs, 12) and gastroenterologists (GIs, 17) reported on treatments given to 91 patients who had experienced at least 1 flare in the past year. Treatment options (increasing dosage of existing treatment, new oral steroid prescription, topical prescription, other prescription, further investigation, and any hospitalisation or surgery) were grouped into 8 distinct treatment patterns. Descriptive statistics and the Fisher exact test were used to assess treatment patterns by type and physician specialty, stratifying by UC status at last assessment (remission vs. mild/moderate). Results: Top treatment patterns for UC relapse/flare included increasing the dosage of existing medication (19% of patients), prescribing a new oral steroid (19%), and prescribing a combination of 2 treatment options (22%). Any hospitalisation or surgery was reported in 7 cases (8%). Adjusting for mild/moderate UC, GIs more often prescribed 2 or 3 combinations of treatment options compared to GPs (30% and 25% vs. 11.5% and 3.8%), and utilised any hospitalisation/surgery as a treatment option (10% vs. 3.8%); GPs were significantly more likely to report prescribing a new oral steroid only compared to GIs (26.9% vs. 10%; p = 0.03). Conclusions: While a variety of treatment options were commonly used to treat UC flares, treatment patterns differed by physician specialty, even when adjusting for disease status. Further research is needed to understand how physician treatment patterns may lead to different outcomes in order to improve UC management in the UK. Background: To characterize the pharmacokinetics (PK) of adalimumab in pediatric patients (pts) with moderate to severe Crohn's disease (CD). Methods: Trough serum adalimumab and anti-drug antibody (AAA) concentrations (conc) were measured in a 52-week (wk) study (N = 189), which had a 4-wk open-label induction phase (dose was determined by pt weight) followed by a 48-wk double-blind maintenance phase (high and low-dose arms). Pts with inadequate response could increase from eow to ew dosing. A non-linear mixed effects modeling (NONMEM ® ) approach was used. Results: At wk 4, the mean±SD adalimumab conc (mg/mL) for pts 40 kg, 15.7±6.55 (160/80 mg), was higher (p < 0.001) than for pts <40 kg, 10.6±6.06 (80/40 mg). For the maintenance phase, the mean±SD adalimumab conc (mg/mL) are listed in the table. Pts receiving ew dosing had higher adalimumab conc at wk 52 (HD: 15.3±11.4, p = 0.065; LD: 6.65±3.49, p = 0.002) compared to those on eow. Anti-TNF naïve pts had slightly higher adalimumab conc than those with prior anti-TNF exposure. Among pts with prior anti-TNF exposure, those with immunogenicity to prior anti-TNF had slightly lower adalimumab levels than those without. Six pts (6/182, 3.3%) were AAA positive during the study; and adalimumab conc were lower in those pts. Pts on concomitant immunosuppressants (azathioprine, 6-mercaptopurine & methotrexate; IMM) had slightly lower (~18%) adalimumab clearance (12.4±5.74 mL/h) compared to pts without IMM (15.2±7.88 mL/h). Only body weight was identified as a statistically significant covariate; but, it explained only 2.6% of total PK variability. A combination of multiple covariates of interest (body weight, albumin, age, sex, CRP, and concomitant IMM) was able to explain <13% of total PK variability. Conclusions: Adalimumab trough conc were maintained in pts receiving eow regimen for 52 wks. Dose escalation was associated with an increase in adalimumab conc compared to eow dosing. Pts with prior anti-TNF exposure (especially those with immunogenicity to prior anti-TNF) tended to have lower adalimumab conc compared to anti-TNF naïve pts. Body weight was the only statistically significant baseline covariate affecting adalimumab clearance, but it accounted for <3% of PK variability.
